Head-To-Head Survey: MeiraGTx (NASDAQ:MGTX) and Biomea Fusion (NASDAQ:BMEA)

MeiraGTx (NASDAQ:MGTX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Institutional and Insider Ownership

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares MeiraGTx and Biomea Fusion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Biomea Fusion	N/A	-253.73%	-97.91%

Analyst Recommendations

This is a breakdown of current ratings for MeiraGTx and Biomea Fusion, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1	0	5	2	3.00
Biomea Fusion	1	0	5	0	2.67

MeiraGTx presently has a consensus price target of $26.17, indicating a potential upside of 93.54%. Biomea Fusion has a consensus price target of $8.20, indicating a potential upside of 521.21%. Given Biomea Fusion’s higher probable upside, analysts plainly believe Biomea Fusion is more favorable than MeiraGTx.

Risk & Volatility

MeiraGTx has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500.

Earnings and Valuation

This table compares MeiraGTx and Biomea Fusion”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39 million	15.95	-$114.20 million	$0.71	19.04
Biomea Fusion	N/A	N/A	-$61.80 million	($0.29)	-4.55

Biomea Fusion has lower revenue, but higher earnings than MeiraGTx. Biomea Fusion is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Summary

MeiraGTx beats Biomea Fusion on 9 of the 13 factors compared between the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About Biomea Fusion

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.